Arena Airs More Mixed Data For Late-Stage Obesity Drug Lorcaserin
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
New Phase III data for Arena Pharmaceuticals' novel obesity compound lorcaserin have disappointed the market once again, even though the company is arguing that technically speaking, they will do the trick in satisfying guidelines for FDA approval
You may also be interested in...
Eisai's Obesity Drug Belviq Passes Cardiovascular Outcomes Test
The Japanese pharma says it will discuss the data with US FDA, with hopes of potential to incorporate secondary endpoint data in labeling.
Vivus Obesity Pill Scores With Phase III Data, But Still Faces Market Hurdles
With complete Phase III results for its obesity drug Qnexa in hand, Vivus has aced one important test on the road to commercialization. But other major hurdles remain - including passing regulatory muster and convincing a partner to sign up to back a drug that combines generic pills
Vivus Obesity Pill Scores With Phase III Data, But Still Faces Market Hurdles
With complete Phase III results for its obesity drug Qnexa in hand, Vivus has aced one important test on the road to commercialization. But other major hurdles remain - including passing regulatory muster and convincing a partner to sign up to back a drug that combines generic pills